XNAS · Healthcare · Drug Manufacturers - Specialty & Generic
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-13 | Q3 2026 | -0.40 | -0.53 | -32.50% | $12.4M | ❌ Miss | +3.56% | -4.44% | — |
| 2026-02-03 | Q2 2026 | -0.40 | -1.05 | -162.50% | $15.2M | ❌ Miss | -5.73% | -11.83% | -0.98% |
| 2025-11-13 |
| Q1 2026 |
| -0.14 |
| -0.08 |
| +42.86% |
| $13.9M |
| ✅ Beat |
| — |
| — |
| — |
| 2025-09-23 | Q4 2025 | -0.04 | -0.25 | -525.00% | $15.1M | ❌ Miss | — | — | — |
| 2025-02-12 | Q2 2025 | 0.00 | -0.28 | -100.00% | $16.2M | ❌ Miss | -0.72% | -0.72% | -13.32% |
| 2024-11-13 | Q1 2025 | -0.34 | -0.20 | +41.18% | $16.6M | ✅ Beat | -11.17% | -14.61% | -17.48% |
| 2024-09-26 | Q4 2024 | -0.45 | -0.82 | -82.22% | $18.0M | ❌ Miss | -17.16% | -15.76% | -26.90% |
| 2024-05-15 | Q3 2024 | -0.64 | -0.52 | +18.75% | $18.0M | ✅ Beat | -3.27% | +2.01% | -6.86% |
Showing last 8 quarters.